Clinical trial

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

NCT06970639

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-09-26

PhasePHASE3

Study timeline

Study start (actual)2024-09-26Date precision: day

Registry last updated2026-08-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLC Patients With Brain Metastasisunresolved

Interventions

Furmonertinib Mesilate TabletsDRUG

Carboplatin InjectionDRUG

Cisplatin for injectionDRUG

Pemetrexed Disodium for InjectionDRUG

Osimertinib Mesylate TabletsDRUG

Sponsors & collaborators

Allist Pharmaceuticals, Inc.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06970639 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.